156 related articles for article (PubMed ID: 37294335)
21. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.
Li XY; Luo DH; Guo L; Mo HY; Sun R; Guo SS; Liu LT; Yang ZC; Yang JH; Qiu F; Sun XS; Wang P; Liu Q; Li JB; Tang QN; Lin C; Yang Q; Liu SL; Liang YJ; Jia GD; Wen DX; Guo CY; Yan JJ; Zhao C; Chen QY; Tang LQ; Mai HQ
J Clin Oncol; 2022 Apr; 40(11):1163-1173. PubMed ID: 34990291
[TBL] [Abstract][Full Text] [Related]
22. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
23. [Highlights from the 2021 ASCO and ESMO annual meetings on radiotherapy of head and neck cancer].
Hecht M; von der Grün J; Semrau S; Müller S; Weissmann T; Gaipl US; Iro H; Fietkau R; Gostian AO
HNO; 2022 Apr; 70(4):258-264. PubMed ID: 35294576
[TBL] [Abstract][Full Text] [Related]
24. Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma.
Zhang Y; Li WF; Mao YP; Guo R; Tang LL; Peng H; Sun Y; Liu Q; Chen L; Ma J
Oncotarget; 2016 Feb; 7(8):9576-85. PubMed ID: 26840023
[TBL] [Abstract][Full Text] [Related]
25. Progress and controversy for the role of chemotherapy in nasopharyngeal carcinoma.
Yoshizaki T; Kondo S; Murono S; Endo K; Tsuji A; Nakanishi Y; Nakanishi S; Sugimoto H; Hatano M; Ueno T; Wakisaka N
Jpn J Clin Oncol; 2015 Mar; 45(3):244-7. PubMed ID: 25583421
[TBL] [Abstract][Full Text] [Related]
26. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
27. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
[TBL] [Abstract][Full Text] [Related]
28. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
29. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
30. Diffusion-weighted imaging as a follow-up modality for evaluation of major salivary gland function in nasopharyngeal carcinoma patients: a preliminary study.
Fan WJ; Teng F; Luo YR; Yu W; Zhang Q; Lu YP; Ma L
Strahlenther Onkol; 2020 Jun; 196(6):530-541. PubMed ID: 32025803
[TBL] [Abstract][Full Text] [Related]
31. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
32. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
[TBL] [Abstract][Full Text] [Related]
33. Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial.
Fu S; Li Y; Han Y; Wang H; Chen Y; Yan O; He Q; Ma H; Liu L; Liu F
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):101-113. PubMed ID: 35074433
[TBL] [Abstract][Full Text] [Related]
34. [Immunotherapy of head and neck cancer : Highlights of the ASCO and ESMO annual meetings 2021].
Theodoraki MN; Laban S; Hoffmann TK
HNO; 2022 Apr; 70(4):271-277. PubMed ID: 35037989
[TBL] [Abstract][Full Text] [Related]
35. Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity-modulated radiotherapy era.
Yang SS; Pang YJ; Wang ZQ; Zhang BY; Liu ZQ; Chen EN; OuYang PY; Xie FY
Cancer Med; 2022 Feb; 11(4):1109-1118. PubMed ID: 34953045
[TBL] [Abstract][Full Text] [Related]
36. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
[TBL] [Abstract][Full Text] [Related]
37. An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
Zhang S; Huang X; Zhou L; Wu G; Lin J; Yang S; Chen J; Lin S
J BUON; 2018; 23(6):1656-1661. PubMed ID: 30610791
[TBL] [Abstract][Full Text] [Related]
38. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.
Fei Z; Xu T; Qiu X; Li M; Chen T; Li L; Huang C; Chen C
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2047-2055. PubMed ID: 33392660
[TBL] [Abstract][Full Text] [Related]
39. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.
Loong HH; Ma BB; Chan AT
Hematol Oncol Clin North Am; 2008 Dec; 22(6):1267-78, x. PubMed ID: 19010273
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes of non-nasopharyngeal lymphoepithelial carcinoma treated with a combined modality approach: A single-institution study.
Qiu Z; Lin F; Lyu S; Xie D; Wang L; Wu Z; Cheng W; Tao Y; Su Y
Cancer Med; 2023 Mar; 12(6):7105-7115. PubMed ID: 36464832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
